Ulcerative Colitis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$14995
Buy Report Download FREE Resources

Published: March 31, 2023 Report Code: GDHC271PIDR-ST

Select Item

Ulcerative Colitis Market Report Overview

The UC market across the 8MM was valued at $6.3 billion in 2021. The market will achieve a CAGR of more than 5% during 2021-2031, which will be driven by an increase in prevalence rates in four of the eight major markets and an increase in diagnosed prevalent cases in seven markets.

Ulcerative Colitis Market Outlook, 2021-2031 ($ Billion)

Ulcerative Colitis Market Outlook, 2021-2031 ($ Billion)

Buy the Full Report to Gain More Information on the Ulcerative Colitis Market Forecast

Download a Free Report Sample

The UC market research covers the 8MM (the US, France, Germany, Italy, Spain, Japan, Canada, and the UK) and provides a forecast model for the ulcerative colitis market through 2031.

Market Size (2021) $6.3 billion
CAGR (2021-2031) >2%
Key Class of Drugs ·       Aminosalicylates

·       Steroids

·       Immunomodulators

·       Anti TNF-Biologics

·       Anti-Interleukin Biologics
Leading Players ·       AbbVie

·       Abivax

·       Bristol Myers Squib

·       Boehringer Ingelheim

·       EA Pharma
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Ulcerative Colitis Market Insights

The crowded market dynamics including the already established biologics market will make the uptake of pipeline drugs more difficult and thereby hampering the market growth. However, the approval and launch of 11 pipeline products such as Roivant Sciences’ RVT-3101, AbbVie’s Skyrizi (risankizumab), among others will propel the market growth during the forecast period.

Ulcerative Colitis - Treatment Insights

  • UC remains incurable and the goal of any pipeline therapy is to induce and maintain remission. For over a decade, anti-TNF-α drugs have been the mainstay of treatment of moderate to severe UC despite their drawbacks.
  • The pipeline agents included in the competitive assessment were compared to Remicade and Entyvio. Remicade has remained the SOC for patients with moderate to severe or worse UC since its approval more than 15 years ago. However, recently, Entyvio has gained traction and now stands with Remicade as a first-line treatment option.
  • Lilly is a newcomer in the IBD space. However, the company is now approaching the treatment of UC with a more refined IL-23 inhibitor than J&J’s Stelara called mirikizumab.

Buy the Full Report for More Ulcerative Colitis Treatment Insights

Download a Free Report Sample

Ulcerative Colitis Market Segmentation by Class of Drugs

The key classes of drugs in the UC market are Aminosalicylates, Steroids, Immunomodulators, Anti TNF-Biologics, and Anti-Interleukin Biologics. There are five marketed biologics in the US for UC: the three TNF inhibitors (Remicade, Humira, and Simponi), an IL-12/IL23 inhibitor (Stelara), and an integrin inhibitor (Entyvio). In 2021, Entyvio was the market-leading biologic for UC in the US.

Buy the Full Report for More Drugs Insights into the Ulcerative Colitis Market

Download a Free Report Sample

Ulcerative Colitis Market - Competitive Landscape

A few of the leading players in the Ulcerative Colitis market are:

  • AbbVie
  • Abivax
  • Bristol Myers Squib
  • Boehringer Ingelheim
  • EA Pharma

The UC market contains a healthy mix of companies that are established in the UC space and companies that are completely new to the disease space. Many of the current players in the UC market are large pharmaceutical companies such as Pfizer and Janssen. A few of the larger companies such as Lilly and Boehringer Ingelheim don’t currently have any products marketed for UC but have agents in the pipeline.

Ulcerative Colitis Market Analysis by Companies

Ulcerative Colitis Market Analysis by Companies

Buy the Full Report for More Ulcerative Colitis Company Insights

Download a Free Report Sample

Scope

This report provides:

  • Overview of ulcerative colitis, including epidemiology, symptoms, diagnosis, and disease management.

  • Annualized ulcerative colitis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the ulcerative colitis market.

  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ulcerative colitis treatment. The most promising candidates in Phase III and Phase IIb development are profiled.

  • Analysis of the current and future market competition in the global ulcerative colitis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

  • Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the 7MM Ulcerative Colitis therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Ulcerative Colitis therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AbbVie
Abivax
Bristol Myers Squib
Boehringer Ingelheim
EA Pharma
Eli Lilly
Galapagos
Gilead
InDex Pharmaceuticals
Janssen
Pfizer
Protagonist Therapeutics
Takeda

Table of Contents

1 Ulcerative Colitis: Executive Summary

1.1 Moderate growth is expected for the UC market from 2021–31

1.2 New competition and biosimilar threats in the UC market

1.3 Novel pipeline to partially address unmet needs

1.4 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Gut dysbiosis

3.1.2 The significance of diet

3.1.3 The role of interleukins

3.1.4 Environmental factors

3.1.5 Epigenetics

3.1.6 Pathophysiology

3.1.7 Biomarkers/targets of interest

3.2 Classification or staging systems

3.3 Symptoms

3.4 Quality of life

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 8MM forecast methodology

4.4.1 Sources used

4.4.2 Forecast assumptions and methods

4.4.3 Diagnosed incident cases of UC

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of UC

4.4.5 Diagnosed prevalent cases of UC by severity

4.4.6 Post-operative UC cases

4.4.7 Pouchitis in diagnosed prevalent cases of UC

4.4.8 Diagnosed prevalent cases of UC by anti- TNF- responsiveness

4.5 Epidemiological forecast for UC (2021-31)

4.5.1 Diagnosed incident cases of UC

4.5.2 Age-specific diagnosed incident cases of UC

4.5.3 Sex-specific diagnosed incident cases of UC

4.5.4 Diagnosed prevalent cases of UC

4.5.5 Age-specific diagnosed prevalent cases of UC

4.5.6 Sex-specific diagnosed prevalent cases of UC

4.5.7 Diagnosed prevalent cases of UC by severity

4.5.8 Pouchitis cases and post-operative UC cases

4.5.9 Diagnosed prevalent cases of UC by anti-TNF responsiveness

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of analysis

4.6.4 Strengths of analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

5.2.1 Preferred treatment options for UC

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Biomarkers or diagnostics to predict responsiveness to therapy

7.3 Lack of highly efficacious treatment alternatives

7.4 Availability of treatments for patients with certain comorbidities

7.5 Standardization of patient-reported outcomes

8 R&D Strategies

8.1 Overview

8.1.1 A focus on interleukin-inhibiting biologics

8.1.2 Targeting new signaling pathways and novel targets

8.1.3 Exploring effective oral therapies

8.2 Clinical trials design

8.2.1 Common efficacy measures in UC clinical trials

8.2.2 Head-to-head clinical trials in UC

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and barriers

12.5 Canada

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Epidemiologist

13.6.4 Epidemiology reviewers

13.6.5 Vice President of Disease Analysis and Intelligence

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

Contact Us

Table

List of Tables

Table 1: UC: Key Metrics in the 8MM

Table 2: Truelove and Witts categorization of disease severity and clinical parameters

Table 3: Montreal classification for the distribution of UC

Table 4: Typical symptoms of UC

Table 5 presents the risk factors and common comorbidities for UC.

Table 6: Treatment guidelines for UC

Table 7: Top 10 deals by value, 2018–22

Table 8: UC market – global drivers and barriers, 2021–31

Table 9: Key events impacting sales for UC in the US, 2021–31

Table 10: UC market – drivers and barriers in the US, 2021—31

Table 11: Key events impacting sales for UC in the 5EU, 2021–31

Table 12: UC Market – drivers and barriers in the 5EU, 2021–31

Table 13: Key events impacting sales for UC in Japan, 2021–31

Table 14: UC market – drivers and barriers in Japan, 2021–31

Table 15: Key events impacting sales for UC in Canada, 2021–31

Table 16: UC market – drivers and barriers in Canada, 2021–31

Table 17: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

List of Figures

Figure 1: Global sales forecast by country for UC in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in UC during the forecast period

Figure 3: Cellular mechanisms involved in the pathogenesis of UC

Figure 4: Types of UC

Figure 5: 8MM, diagnosed incidence of UC (cases per 100,000 population), men and women, all ages, 2021

Figure 6: 8MM, diagnosed prevalence of UC (%), men and women, all ages, 2021

Figure 7: 8MM, sources used and not used to forecast the diagnosed incident cases of UC

Figure 8: 8MM, sources used and not used to forecast the diagnosed prevalent cases of UC

Figure 9: 8MM, sources used to forecast the diagnosed prevalent cases of UC by severity

Figure 10: 8MM, sources used to forecast the post-operative UC cases

Figure 11: 8MM, sources used to forecast the pouchitis cases among the diagnosed prevalent cases of UC

Figure 12: 8MM, sources used to forecast the diagnosed prevalent cases of UC by anti-TNF responsiveness

Figure 13: 8MM, diagnosed incident cases of UC, N, both sexes, all ages, 2021

Figure 14: 8MM, diagnosed incident cases of UC by age group, N, both sexes, 2021

Figure 15: 8MM, diagnosed incident cases of UC by sex, N, all ages, 2021

Figure 16: 8MM, diagnosed prevalent cases of UC, N, both sexes, all ages, 2021

Figure 17: 8MM, diagnosed prevalent cases of UC by age group, N, both sexes, 2021

Figure 18: 8MM, diagnosed prevalent cases of UC by sex, N, all ages, 2021

Figure 19: 8MM, diagnosed prevalent cases of UC by severity, N, both sexes, ages <18 years, 2021

Figure 20: 8MM, diagnosed prevalent cases of UC by severity, N, both sexes, ages ≥18 years, 2021

Figure 21: 8MM, pouchitis cases and post-operative UC cases, N, both sexes, all ages, 2021

Figure 22: 8MM, diagnosed prevalent cases of UC by anti-TNF responsiveness, N, both sexes, all ages, 2021

Figure 23: Typical treatment algorithm for newly presenting UC patients

Figure 24: Unmet needs and opportunities in UC, 2022

Figure 25: Overview of the development pipeline in UC

Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for UC in the 8MM during the forecast period, 2021–31

Figure 27: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOCs, Remicade and Entyvio

Figure 28: Analysis of the company portfolio gap in UC dDuring the forecast period

Figure 29: Global (8MM) sales forecast by country for UC in 2021 and 2031

Figure 30: Global (8MM) sales forecast by MOA for UC in 2021 and 2031

Figure 31: Sales forecast by class for UC in the US in 2021 and 2031

Figure 32: Sales forecast by class for UC in the 5EU in 2021 and 2031

Figure 33: Sales forecast by class for UC in Japan in 2021 and 2031

Figure 34: Sales forecast by class for UC in Canada in 2021 and 2031

Frequently asked questions

Ulcerative Colitis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031 standard reports
Currency USD
$14,995

Can be used by individual purchaser only

Most Popular
$29,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$44,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Ulcerative Colitis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Ulcerative Colitis reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ulcerative Colitis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031 in real time.

  • Access a live Ulcerative Colitis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more